Shares of Diurnal Group PLC (LON:DNL) hit a new 52-week high on Monday . The company traded as high as GBX 215.80 ($2.98) and last traded at GBX 215.80 ($2.98), with a volume of 2434 shares. The stock had previously closed at GBX 211 ($2.92).
Separately, Numis Securities restated a “buy” rating and issued a GBX 185 ($2.56) target price on shares of Diurnal Group in a research report on Tuesday, February 13th.
The company has a market cap of $184.17 and a PE ratio of -1,198.89.
In other news, insider John Goddard purchased 10,791 shares of the firm’s stock in a transaction on Friday, January 5th. The stock was purchased at an average cost of GBX 540 ($7.46) per share, with a total value of £58,271.40 ($80,507.60).
TRADEMARK VIOLATION NOTICE: “Diurnal Group (DNL) Reaches New 12-Month High at $215.80” was posted by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.tickerreport.com/banking-finance/3257832/diurnal-group-dnl-reaches-new-12-month-high-at-215-80.html.
About Diurnal Group
Diurnal Group plc is a clinical-stage pharmaceutical company. The Company is engaged in developing hormone therapeutics to aid treatment for various endocrine conditions. The Company’s products include Chronocort, which is engaged in developing hydrocortisone product for the treatment of congenital adrenal hyperplasia and adrenal insufficiency; Infacort, which is engaged in creating paediatric hydrocortisone replacement product for neonates and infants suffering from adrenal insufficiency; Native Oral Testosterone, which is engaged in creating oral testosterone treatment for hypogonadism, and Tri4Combi, which is engaged in developing combination therapy product of thyroid hormones for patients suffering from hypothyroidism.
Receive News & Ratings for Diurnal Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diurnal Group and related companies with MarketBeat.com's FREE daily email newsletter.